Most Popular Reagents
Instruments
Antibodies
ELISA Kits
Protein Electrophoresis and Blotting
Protein and Antibody Purification
Recombinant Proteins
Molecular Biology
Stable Cell Lines
Cell Isolation and Activation
IVD Raw Materials
Therapy Applications
Resources
| $211.00 | |
| A01932-40 | |
|
|
|
|
|
|
|
|
|
| Ask us a question | |
| Specificity | The product is specific for Tocilizumab. This antibody serves as an excellent positive control for Tocilizumab immunogenicity (ADA) assays. |
| Host Species | Rabbit |
| Immunogen | Tocilizumab |
| Conjugate | Unconjugated |
| Working concentrations for specific applications should be determined by the investigators. The appropriate concentration may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product. | |||||
|
|||||
| Form | Lyophilized |
| Storage Buffer | lyophilized with PBS, pH 7.4, contains 0.02% sodium azide. |
| Reconstitution | Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL. |
| Storage Instructions | The lyophilized product remains stable for 1 year at -20℃ from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8℃ or for 12 months at -20℃ or below. Avoid freeze/thaw cycles. |
| Purification | Antigen affinity purification |
| Isotype | Rabbit IgG |
| Clonality | Polyclonal |
| Clone ID | Not applicable |
| Note | GenScript can customize this product per customer's request including product size, buffer components, etc. |
»
ELISA binding of Anti-Tocilizumab Antibody, pAb, Rabbit (GenScript, A01932-40) with Tocilizumab.
Coating antigen: Tocilizumab, 1 µg/ml.
Anti-Tocilizumab Antibody, pAb, Rabbit (GenScript, A01932-40) dilution start from 1,000 ng/ml, EC₅₀= 2.247 ng/ml. »
| Target Background | Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann–La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects. |
| Synonyms | Rabbit polyclonal to Actemra |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
